Abnormal lipids in high-risk patients achieving cholesterol targets: a cross-sectional study of routinely collected UK general practice data

References

• Anderson KM, Odell PM, Wilson PW. et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–81Anderson KM, Odell PM, Wilson PW. et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–8
   PubMed Web of Science ®Google Scholar
• Wood D, Wray R, Poulter N. et al. for JBS2: Joint British Societies Guidelines on prevention of CVD in clinical practice. Heart 2005;91(Suppl):V1–522Wood D, Wray R, Poulter N. et al. for JBS2: Joint British Societies Guidelines on prevention of CVD in clinical practice. Heart 2005;91(Suppl):V1–52
   PubMedGoogle Scholar
• Quality and outcomes framework guidance: Summary of Indicators - clinical domain, February 2006. http://www.bma.org.uk/ap.nsf/Content/qof06~summclinical [Accessed 18/03/08]3Quality and outcomes framework guidance: Summary of Indicators - clinical domain, February 2006. http://www.bma.org.uk/ap.nsf/Content/qof06~summclinical [Accessed 18/03/08]
   Google Scholar
• Clinical and Health Outcomes Knowledge Base. http://www.nchod.nhs.uk/ [Accessed 18/03/08]4Clinical and Health Outcomes Knowledge Base. http://www.nchod.nhs.uk/ [Accessed 18/03/08]
   Google Scholar
• de Lusignan S, Belsey J, Hague N. et al. Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. J Public Health (Oxf) 2006; 28:361–95de Lusignan S, Belsey J, Hague N. et al. Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. J Public Health (Oxf) 2006; 28:361–9
   PubMed Web of Science ®Google Scholar
• NHS. Connecting for Health: MIQUEST. http://www.connectingforhealth.nhs.uk/systemsandservices/data/miquest [Accessed 18/03/08]6NHS. Connecting for Health: MIQUEST. http://www.connectingforhealth.nhs.uk/systemsandservices/data/miquest [Accessed 18/03/08]
   Google Scholar
• van Vlymen J, de Lusignan S. A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data. Inform Prim Care 2005;13:281–917van Vlymen J, de Lusignan S. A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data. Inform Prim Care 2005;13:281–91
   PubMedGoogle Scholar
• van Vlymen J, de Lusignan S, Hague N. et al. Ensuring the quality of aggregated General Practice data: Lessons from the Primary Care Data Quality Programme (PCDQ). Stud Health Technol Inform 2005;116:1010–158van Vlymen J, de Lusignan S, Hague N. et al. Ensuring the quality of aggregated General Practice data: Lessons from the Primary Care Data Quality Programme (PCDQ). Stud Health Technol Inform 2005;116:1010–15
   PubMedGoogle Scholar
• Department of Health. Prescription Cost Analysis: England 2006 http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-2006 [Accessed 18/03/08]9Department of Health. Prescription Cost Analysis: England 2006 http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-2006 [Accessed 18/03/08]
   Google Scholar
• ISD Scotland. Prescription Cost Analysis for Scotland: Year ending 31 March 2007. http://www.isdscotland.org/isd/files/final_F07.xls [Accessed 18/03/08]10ISD Scotland. Prescription Cost Analysis for Scotland: Year ending 31 March 2007. http://www.isdscotland.org/isd/files/final_F07.xls [Accessed 18/03/08]
   Google Scholar
• Health Solutions Wales. Prescription Cost Analysis Wales 2006. http://www.wales.nhs.uk/sites3/Documents/428/PCA%20Wales%202006.xls [Accessed 18/03/08]11Health Solutions Wales. Prescription Cost Analysis Wales 2006. http://www.wales.nhs.uk/sites3/Documents/428/PCA%20Wales%202006.xls [Accessed 18/03/08]
   Google Scholar
• Central Services Agency. Prescription Cost Analysis: Northern Ireland 2006. http://www.centralservicesagency.n-i.nhs.uk/files/statistics/file/PCT%202006.xls [Accessed 18/03/08]12Central Services Agency. Prescription Cost Analysis: Northern Ireland 2006. http://www.centralservicesagency.n-i.nhs.uk/files/statistics/file/PCT%202006.xls [Accessed 18/03/08]
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–7813Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78
   PubMed Web of Science ®Google Scholar
• LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340–614LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340–6
   PubMed Web of Science ®Google Scholar
• Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag 2005;1:317–3115Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag 2005;1:317–31
   PubMedGoogle Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA. et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004;20:627–3716Athyros VG, Mikhailidis DP, Papageorgiou AA. et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004;20:627–37
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC. et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301–1017Barter P, Gotto AM, LaRosa JC. et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301–10
   PubMed Web of Science ®Google Scholar
• Superko HR, King S, III. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008;117:560–818Superko HR, King S, III. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008;117:560–8
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237–4519Frick MH, Elo O, Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237–45
   Google Scholar
• Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410–1820Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410–18
   PubMed Web of Science ®Google Scholar
• Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–8121Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–81
   PubMed Web of Science ®Google Scholar
• Robins SJ, Collins D, Wittes JT. et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585–9122Robins SJ, Collins D, Wittes JT. et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585–91
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK. et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245–5523Canner PL, Berge KG, Wenger NK. et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245–55
   PubMed Web of Science ®Google Scholar
• HPS-2/THRIVE http://www.ctsu.ox.ac.uk/pressreleases/2006-05-31/hps2-thrive-press-release [Accessed 18/03/08]24HPS-2/THRIVE http://www.ctsu.ox.ac.uk/pressreleases/2006-05-31/hps2-thrive-press-release [Accessed 18/03/08]
   Google Scholar
• AIM-HIGH http://accelerator.axioresearch.com/aim-high/ [Accessed 18/03/08]25AIM-HIGH http://accelerator.axioresearch.com/aim-high/ [Accessed 18/03/08]
   Google Scholar
• Ginsberg HN, Bonds DE, Lovato LC. et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:56–67i26Ginsberg HN, Bonds DE, Lovato LC. et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:56–67i
   PubMed Web of Science ®Google Scholar
• IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs. Simvastatin (Study P04103) http://clinicaltrials.gov/show/NCT00202878 [Accessed 01/07/08]27IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs. Simvastatin (Study P04103) http://clinicaltrials.gov/show/NCT00202878 [Accessed 01/07/08]
   Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM. et al. Meta-anal-ysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009–2628Mikhailidis DP, Sibbring GC, Ballantyne CM. et al. Meta-anal-ysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009–26
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–9729Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Merck & Co Inc. ZOCOR prescribing information. 2008 http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf [Accessed 25/6/08]30Merck & Co Inc. ZOCOR prescribing information. 2008 http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf [Accessed 25/6/08]
   Google Scholar
• Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol 2006;97(Suppl):52–60C31Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol 2006;97(Suppl):52–60C
   PubMed Web of Science ®Google Scholar
• Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002;90(Suppl):50–60K32Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002;90(Suppl):50–60K
   PubMed Web of Science ®Google Scholar
• Havranek JM, Wolfsen AR, Warnke GA. et al. Monotherapy with ezetimibe causing myopathy. Am J Med 2006;119:285–633Havranek JM, Wolfsen AR, Warnke GA. et al. Monotherapy with ezetimibe causing myopathy. Am J Med 2006;119:285–6
   PubMed Web of Science ®Google Scholar
• Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol 2006;22:141–434Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol 2006;22:141–4
   PubMed Web of Science ®Google Scholar
• Weffald LA, Flach LA. Myopathy associated with atorvastatin-ezetimibe combination therapy. Pharmacotherapy 2007;27: 309–1135Weffald LA, Flach LA. Myopathy associated with atorvastatin-ezetimibe combination therapy. Pharmacotherapy 2007;27: 309–11
   PubMed Web of Science ®Google Scholar
• Gharavi AG, Diamond JA, Smith DA. et al. Niacin-induced myopathy. Am J Cardiol 1994;74:841–236Gharavi AG, Diamond JA, Smith DA. et al. Niacin-induced myopathy. Am J Cardiol 1994;74:841–2
   PubMed Web of Science ®Google Scholar
• Goldstein MR. Nicotinic acid-associated myopathy. Am J Med 1989;87:24837Goldstein MR. Nicotinic acid-associated myopathy. Am J Med 1989;87:248
   PubMed Web of Science ®Google Scholar
• Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med 1989;86:481–338Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med 1989;86:481–3
   PubMed Web of Science ®Google Scholar
• Knopp RH, Gitter H, Truitt T. et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729–4139Knopp RH, Gitter H, Truitt T. et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729–41
   PubMed Web of Science ®Google Scholar
• Dujovne C, Ettinger MP, McNeer JF. et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092–740Dujovne C, Ettinger MP, McNeer JF. et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092–7
   PubMed Web of Science ®Google Scholar
• Patel J, Kirby M, Hughes EA. The Lipid Audit: analysis of lipid management in two centres in Britain 2003. Br J Cardiol 2004; 11:214–1741Patel J, Kirby M, Hughes EA. The Lipid Audit: analysis of lipid management in two centres in Britain 2003. Br J Cardiol 2004; 11:214–17
   Google Scholar
• Van Ganse E, Laforest L, Burke T. et al. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Clin Ther 2007;29:1671–8142Van Ganse E, Laforest L, Burke T. et al. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Clin Ther 2007;29:1671–81
   PubMed Web of Science ®Google Scholar
• Bruckert E, Baccara-Dinet M, McCoy F. et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005;21:1927–3443Bruckert E, Baccara-Dinet M, McCoy F. et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005;21:1927–34
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Hague N, Belsey J. et al. The ‘rule of halves’ still applies to the management of cholesterol in cardiovascular disease: 2002-2005. Br J Cardiol 2006;13:145–5344de Lusignan S, Hague N, Belsey J. et al. The ‘rule of halves’ still applies to the management of cholesterol in cardiovascular disease: 2002-2005. Br J Cardiol 2006;13:145–53
   Google Scholar
• de Lusignan S. An educational intervention, involving feedback of routinely collected computer data, to improve cardiovascular disease management in UK primary care. Methods Inf Med 2007;46:57–6245de Lusignan S. An educational intervention, involving feedback of routinely collected computer data, to improve cardiovascular disease management in UK primary care. Methods Inf Med 2007;46:57–62
   PubMed Web of Science ®Google Scholar